Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of N-Acetyl-L-Leucine on GM2 Gangliosdisosis (Tay-Sachs and Sandhoff Disease): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study

Trial Profile

Effects of N-Acetyl-L-Leucine on GM2 Gangliosdisosis (Tay-Sachs and Sandhoff Disease): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs L-Acetylleucine (Primary)
  • Indications GM2 gangliosidoses; Sandhoff disease; Tay-Sachs disease
  • Focus Therapeutic Use
  • Sponsors IntraBio
  • Most Recent Events

    • 18 Sep 2019 According to an IntraBio media release, this trial has been accepted by Independent Ethics Committees (IEC), and the Spanish Agency of Medicines and Medical Products (AEMPS) as well as National Regulatory Agencies in Germany, Slovakia, the United Kingdom, and the US Food and Drug Administration (IND 142302).
    • 18 Sep 2019 According to an IntraBio media release, this trial is open for recruitment in Spain.
    • 15 Sep 2019 According to an IntraBio media release, this trial is open for recruitment in Germany. Two trial sites have been officially established in Germany: Ludwig Maximilian University (LMU) of Munich and the University of Giessen. As of September, LMU Munich is actively recruiting patients and it is planned the University of Giessen will begin recruitment in October 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top